These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23999647)

  • 1. Clinical significance of the appearance of abnormal protein band in patients with multiple myeloma.
    Jo JC; Yoon DH; Kim S; Lee K; Kang EH; Jang S; Park CJ; Chi HS; Huh J; Park CS; Suh C
    Ann Hematol; 2014 Mar; 93(3):463-9. PubMed ID: 23999647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal protein bands in patients with multiple myeloma after haematopoietic stem cell transplantation: does it have a prognostic significance?
    Sucak G; Suyanı E; Özkurt ZN; Yeğin ZA; Aki Z; Yagci M
    Hematol Oncol; 2010 Dec; 28(4):180-4. PubMed ID: 20155734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical significance of abnormal protein bands in multiple myeloma treated with bortezomib-based induction regimen and autologous stem cell transplantation].
    Wang HH; Li J; Liu JR; Zheng D; Gu JL; Yan MS; Zou WY; Xu DR
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):327-31. PubMed ID: 23668206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isotype class switching after transplantation in multiple myeloma.
    Maisnar V; Tichý M; Smolej L; Zák P; Radocha J; Palicka V; Malý J; Bláha V
    Neoplasma; 2007; 54(3):225-8. PubMed ID: 17447854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
    O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
    Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
    Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligoclonal bands and immunoglobulin isotype switch during monitoring of patients with multiple myeloma and autologous hematopoietic cell transplantation: a 16-year experience.
    Alejandre ME; Madalena LB; Pavlovsky MA; Facio ML; Corrado C; Milone G; Bresciani PD; Fraind SA; Pavlovsky S; Pizzolato MA
    Clin Chem Lab Med; 2010 May; 48(5):727-31. PubMed ID: 20450334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients.
    Krejci M; Hajek R; Buchler T; Krivanova A; Svobodnik A; Pour L; Adam Z; Mayer J; Vorlicek J
    Neoplasma; 2007; 54(2):143-8. PubMed ID: 17319788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
    Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E
    Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effects of autologous stem cell transplantation as consolidation treatment in 70 multiple myeloma patients: a case-controlled study.
    Zhou LL; Yuan ZG; Fu WJ; Xi H; Zhang CY; Lan HF; Zhang X; Chen Y; Liu WY; Hou J
    Chin Med J (Engl); 2011 Oct; 124(19):2975-80. PubMed ID: 22040538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.
    Chong YP; Kim S; Ko OB; Koo JE; Lee D; Park SH; Park SJ; Lee D; Kim SW; Suh C
    J Korean Med Sci; 2008 Oct; 23(5):819-24. PubMed ID: 18955788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.
    Krejci M; Buchler T; Hajek R; Svobodnik A; Krivanova A; Pour L; Adam Z; Mayer J; Vorlicek J
    Bone Marrow Transplant; 2005 Jan; 35(2):159-64. PubMed ID: 15543200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
    Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
    Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma.
    Kim JE; Yoo C; Lee DH; Kim SW; Lee JS; Suh C
    Ann Hematol; 2010 Apr; 89(4):391-7. PubMed ID: 19844712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.